Viking Therapeutics (VKTX) news
Recent news
Viking Therapeutics announces initiation of VK2735 oral phase 3 clinical program in patients with obesity
AInvest Wire · 1d agoViking Therapeutics, Inc.: Truist Securities cuts target price to $85 from $87
Truist Securities has revised its target price for Viking Therapeutics, Inc. (VKTX) to $85 per share, down from the previous $87, while maintaining its "Buy" rating . The adjustment reflects updated analyst assessments of the company’s near-term outlook and market positioning. Despite the reduced…
AInvest Wire · Oct 7, 2026Viking Therapeutics announces initiation of VK2735 oral maintenance dosing clinical trial in patients with obesity
AInvest Wire · Oct 6, 2026Viking Therapeutics shares down 15% after co prices upsized stock, convertible offerings
Viking Therapeutics (Nasdaq: VKTX) announced its intention to raise $200.0 million through a public offering of common stock and an additional $200.0 million in convertible senior notes due 2032, with both offerings registered under the Securities Act of 1933, as amended. The company also granted…
AInvest Wire · Sep 24, 2026Viking Therapeutics, - Offering size increased to $275 mln common stock and $225 mln notes
Viking Therapeutics, Inc. (Nasdaq: VKTX) has increased the size of its proposed capital raise, announcing plans to offer $275 million of common stock and $225 million aggregate principal amount of convertible senior notes due 2032, up from the previously announced $200 million each. The company has…
AInvest Wire · Sep 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.